Entries |
Document | Title | Date |
20080214676 | DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS - The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. | 09-04-2008 |
20080214677 | Chitosan-Silicon Dioxide Coprecipitate and Use as Excipient in Solid Dosage Forms - Chitosan silicon dioxide coprecipitate composition, method of production thereof, pharmaceutical composition comprising the chitosan silicon dioxide coprecipitate composition and use of the chitosan silicon dioxide coprecipitate composition for manufacturing a sustained or immediate release formulation. | 09-04-2008 |
20080262095 | Protectant for UV-Induced Skin Damage - The present invention provides a method for protecting against UV radiation-induced skin damage. Specifically, compositions including dapsone are administered to provide UV protection. The dapsone compositions may be administered orally, or by other parenteral routes, such as topically, transdermally, by inhalation, and the like. | 10-23-2008 |
20080319085 | TITRATION DOSING REGIMEN FOR CONTROLLED RELEASE TRAMADOL - A titration dosing regimen for the administration of controlled release tramadol analgesic to patients. The titration dosing regimen provides a significant reduction in the occurrence of adverse effects from the introduction of controlled released tramadol dosing, thus increasing patient compliance and medication tolerability. | 12-25-2008 |
20090012179 | Use of Tyrphostins to Stimulate Neurite Outgrowth - Disclosed herein are several methods for promoting nerve regeneration. The methods include administering at least one tyrphostin, or a pharmaceutically acceptable salt thereof. In one non-limiting example, the tyrphostin is tyrphostin A9. These methods can be used to promote nerve growth in the central or peripheral nervous system. The methods are of use in treating neurodegenerative diseases, such as Parkinson's disease, or in treating the transaction of a partial or complete transaction of a nerve in the peripheral or central nervous system. | 01-08-2009 |
20090069439 | Use of pargyline for the treatment of hair folliclies - Use of Pargyline for the production of a medicament for influencing the metabolism of hair follicles and the modulation of their vital cycle. | 03-12-2009 |
20090076159 | DEUTERIUM-ENRICHED EPLIVANSERIN - The present application describes deuterium-enriched eplivanserin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090082466 | Abuse Resistant and Extended Release Formulations and Method of Use Thereof - The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioids, extended release pharmaceutical compositions of opioids and extended release abuse resistant pharmaceutical compositions of opioids and the use thereof for the treatment of pain. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of opioid abuse and/or opioid toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of opioid abuse and/or opioid toxicity from either intentional or unintentional tampering. | 03-26-2009 |
20090137684 | SUSTAINED-RELEASE PREPARATIONS AND METHOD FOR PRODUCING THE SAME - The present invention relates to sustained-release preparations prepared by double granulation and methods for producing the same. The sustained-release preparations according to the present invention enables maintenance of effective blood concentration of drug for many hours via sustained release of the drug over 12 hours or more, and further its production is easy owing to convenience of process. | 05-28-2009 |
20090143478 | Milled Submicron Organic Biocides With Narrow Particle Size Distribution, and Uses Thereof - A method of milling substantially insoluble solid organic biocides to form a micron or sub-micron product having a narrow particle size distribution is presented. The milling involves wet milling of the organic biocide with high density milling media having a diameter between 0.1 mm and 0.8 mm, preferably between 0.2 mm and 0.7 mm, and a density equal to or greater than 3.8 g/cc, preferably greater than 5.5 g/cc, in a ball mill using between about 40% and 80% loading of the mill volume with milling media, and having the organic biocide suspended in an aqueous milling liquid which comprises one or more surface active agents. The milling speed is preferably high, for example from about 1000 rpm to about 4000 rpm. The milled product can be used in foliar applications at a lower effective dosage than prior art formulations, can be used in improved antifouling paint formulations, and can be used in new applications such as the direct injection of solid organic biocide particulates in wood to act as a long lasting wood preservative. | 06-04-2009 |
20090149548 | NOVEL 1,2-DIPHENYLETHENE DERIVATIVES FOR TREATMENT OF IMMUNE DISEASES - The invention provides novel 1,2-diphenylethene derivatives and pharmaceutically acceptable salts thereof, the process for production of these compounds and their pharmaceutical composition and the use of these compounds as modulators of T-cells, neutrophils, macrophages and their associated cytokines as agents for treating immune, inflammatory and auto-immune diseases. | 06-11-2009 |
20090156684 | LIQUID ANTIBACTERIAL COMPOSITIONS INCORPORATING TRICHLOROCARBANILIDE WITH REDUCED WATER ACTIVITY - A liquid antibacterial soap comprising trichlorocarbanilide, wherein the composition includes, 0.1-5 wt. % trichlorocarbanilide, 0-40 wt. % water, 0.1-40 wt. % of a surfactant or mixture of surfactants, 10-60 wt. % of lower glycols to render the composition visually clear and stable, and 0.1-10 wt. % of a mixture of additional adjuvant ingredients. | 06-18-2009 |
20090163599 | Mif adsorbant - The present invention concerns an apheresis material or adsorbant and a method for removing, depleting or inactivating MIF (macrophage migration inhibitory factor) from blood, blood plasma, blood serum or other body fluids. The present invention is also concerned with the use of said apheresis material or adsorbant. In order to prepare a novel means and novel method, which can reduce the activity or amount of the mediator for sepsis and septic shock, MIF, in a patient's body fluid in a manner which is more pleasant and tolerable for the patient than prior art means and methods, the invention proposes that the apheresis material or adsorbant comprises a solid carrier material on the surface of which MIF-binding molecules or functional groups are immobilized. The method proposes that the apheresis material or adsorbant be brought into contact extracorporeally with the blood, blood plasma, blood serum or other body fluids. | 06-25-2009 |
20090197967 | COMPOSITIONS AND METHODS FOR TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS - Provided herein are compositions and methods for treating ophthalmic diseases and disorders. Compositions comprising retinylamine derivative compounds provided herein are useful for treating and preventing ophthalmic diseases and disorders, including diabetic retinopathy diabetic maculopathy, diabetic macular edema, retinal ischemia, ischemia-reperfusion related retinal injury, and metabolic optic neuropathy. | 08-06-2009 |
20090326074 | Alkoxy compounds for disease treatment - The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. | 12-31-2009 |
20100029781 | METHODS FOR PREPARATION OF ANTI-ACNE FORMULATION AND COMPOSITIONS PREPARED THEREBY - The present invention provides methods to make solvent-microparticle (SMP) topical formulations for bioactive drugs. The formulations, which are aqueous gels containing undissolved solid drug, include a drug in a solution which can permeate the stratum corneum layer of the epidermis and the drug in an undissolved microparticulate solid form that does not readily cross the stratum corneum. The solid form is retained in or above the stratum corneum to serve as a reservoir or to provide drug action in the supracorneum zone. The fine, particulate solid component of the invention can confer a smooth, nongritty feel against the skin. | 02-04-2010 |
20100063159 | Use of dapsone as a neuroprotector in cerebral infarction - The use of dapsone is the first effective treatment against the disabling consequences associated with cerebral infarction in patients. Dapsone was evaluated as a neuroprotector in the cerebral infarction model produced by the occlusion of the middle cerebral artery in rats and in patients suffering from acute cerebral infarction caused by thromboembolism. In both studies, dapsone displayed a reduction of between 70 and 90% in the adverse effects which occur as a consequence of the infarction. | 03-11-2010 |
20100069503 | INHIBITION OF MITOGEN-ACTIVATED PROTEIN KINASES IN CARDIOVASCULAR DISEASE - The present invention relates to methods for inhibiting subacute thrombosis and/or intimal hyperplasia following an interventional vascular procedure by contacting a blood vessel or a synthetic material with a mitogen-activated protein kinase (MAPK) pathway inhibitor. The present invention further relates to vascular devices comprising a MAPK pathway inhibitor. | 03-18-2010 |
20100076085 | HCl Polymorphs of 3-((2-(Dimethylamino)methyl-(cyclohex-1-yl))phenol - A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states. | 03-25-2010 |
20100099773 | INCLUSION COMPLEX OF SIBUTRAMINE AND BETA-CYCLODEXTRIN - The present invention relates to a sibutramine-containing inclusion complex having superior storage stability, and particularly to a pharmaceutically stable inclusion complex suitable for the drug formulation, which prepared by reacting a sibutramine (N,N-dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine) of Formula 1 and beta-cyclodextrin in a predetermined ratio, its preparation method and a pharmaceutical composition comprising the same. | 04-22-2010 |
20100099774 | Method for Controlling Harmful Fungi - The present invention relates to a method for controlling phytopathogenic fungior harmful fungi in the protection of materials, wherein the fungi or the materials, plants, soil or seed to be protected against fungal attack are treated with a fungicidally effective amount of an amidrazone of the formula (I) wherein R, R | 04-22-2010 |
20100113605 | METHODS, COMPOSITIONS AND USES THEREOF - The invention relates to a method for identifying a candidate compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission in the central nervous system, the method comprising the following steps: (a) providing a compound to be tested; (b) testing the ability of the compound to bind to the cocaine-binding site of a monoamine reuptake transporter; and (c) testing the ability of the compound to modulate the inward or outward transport of monoamine neurotransmitters via the monoamine reuptake transporter, wherein the test compound is identified as a candidate compound for treating a disorder or condition associated’ with dysfunction of monoamine neurotransmission if it is able to bind to the cocaine-binding site of the monoamine reuptake transporter and modulate its activity. The invention further relates to compounds identified using the method of the invention, and uses, compositions and medicaments thereof. | 05-06-2010 |
20100190861 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS - The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. | 07-29-2010 |
20100210732 | Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor - The present invention is directed to pharmaceutical compositions and the use thereof for preventing or minimizing the intensity of the serotonin syndrome. The present invention is directed at a method of preventing or minimizing the intensity of the serotonin syndrome in humans which comprises administering proserotonergic agents and serotonin surge protectors, wherein said concurrent administration reduces or prevents serotonin excess, which is the cause of the serotonin syndrome. The present invention is also directed to pharmaceutical compositions comprising proserotonergic agents and serotonin surge protectors useful for carrying out the method of the present invention. | 08-19-2010 |
20100222434 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION - The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound of the formula (I) or a pharmaceutically acceptable salt thereof to a mammal which may be diagnosed with an amyloid-β protein-related disease; and so on. | 09-02-2010 |
20100280126 | Method of Inhibiting Inflammatory Pain - A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amount of a (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol compound or a physiologically acceptable salt thereof, such as the hydrochloride or citrate salt. | 11-04-2010 |
20110060053 | Crystalline Modifications of 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol - Crystalline modifications of (1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol and mixtures thereof, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for the enrichment of (1R,3R,6R)- or (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol. | 03-10-2011 |
20110092602 | RAPIDLY DISINTEGRATING ORAL COMPOSITIONS OF TRAMADOL - The present invention relates to a stable taste masked orally disintegrating pharmaceutical composition of tramadol comprising of 3% to 30% w/w of tramadol, 2% to 30% w/w of an ion exchange resin, 0.01 to about 2% w/w of binder and pharmaceutically acceptable excipients to equal 100% w/w, wherein the binder used is gelatin. | 04-21-2011 |
20110152379 | COMPOSITION FOR CONTROL OF AGING AND/OR EXTENSION OF LIFE, CONTAINING DAPSONE AS ACTIVE INGREDIENT - The present invention relates to a composition for controlling aging and/or extending lifespan. More specifically, the present invention relates to a composition containing dapsone as an effective component for controlling aging and/or extending lifespan, in which when applying the composition according to the present invention to an object, the effect of controlling aging or extending lifespan is excellent. Specifically, the treatment of dapsone (DDS) increases the lifespan of | 06-23-2011 |
20110251286 | Crystalline salts and/or co-crystals of O-desmethyltramadol - Salts and/or co-crystals of (+)-3-[2-(dimethylamino)-methyl-1-hydroxycyclohexyl]-phenol or of (−)-3-[2-(dimethylamino)methyl-1-hydroxy-cyclohexyl]phenol, present in crystalline form, with cinnamic acid, C | 10-13-2011 |
20110269840 | TREATING RENAL CANCER USING A 4-[BIS[2-[(METHYLSULFONYL)OXY]ETHYL]AMINO]-2-METHYL-BENZALDEHYDE - The present invention features methods of treating a mammalian subject having renal cancer by administration of certain dimethylsulfonate compounds, such as a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration protocols and dosing schedules for methods of treating patients having renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein. | 11-03-2011 |
20110294896 | Topical Treatment With Dapsone In G6PD-Deficient Patients - The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, and wherein the composition also contains dapsone in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The present invention also discloses the treatment of dermatological conditions in G6PD-deficient patients with the composition, while avoiding adverse hematologic effects. | 12-01-2011 |
20110306673 | CRYSTALLINE FORMS OF (1RS,2RS,6RS)-6-DIMETHYLAMINOMETHYL-1-(3-METHOXYPHENYL)CYCLOHEXANE-1,3-DI- OL HYDROCHLORIDE - This invention relates to solid crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutical compositions comprising 1. | 12-15-2011 |
20120035269 | CYCLOPROPENE AMINE COMPOUNDS - Methods of applying cyclopropene amine derivatives and compositions thereof to inhibit ethylene receptors in plants and plant material are disclosed. Methods include applying to the plant an effective ethylene response-inhibiting amount of at least one cyclopropene amine compound or composition thereof. Cyclopropene amine compounds, enantiomers, stereoisomers or salts thereof are also provided. | 02-09-2012 |
20120059065 | Tamper Resistant Dosage Form Comprising An Anionic Polymer - A pharmaceutical dosage form and method of using same, the pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing
| 03-08-2012 |
20120157541 | SOLUBLE PHARMACEUTICAL FORMULATIONS OF N,N-DIAMINODIPHENYL SULFONE FOR OPTIMAL USE IN THE TREATMENT OF VARIOUS DISEASES - The present invention aims to demonstrate that a soluble pharmaceutical formulation can be prepared of N,N′-Diamino-diphenyl sulfone which is useful in the development of an ideal drug for use against cerebral infarction, epilepsy, traumatic spinal cord injury, cranio-encephalic trauma, leprosy, | 06-21-2012 |
20120225949 | COMPOSITIONS AND METHODS FOR TREATING BIPOLAR DISORDER - The present invention is directed to a method for treating symptoms associated with bipolar disorder. The method includes administering to a subject in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with bipolar disorder, childhood-onset bipolar disorder, or childhood-onset bipolar disorder with Fear of Harm. | 09-06-2012 |
20130005821 | INTRAVENOUS ADMINISTRATION OF TRAMADOL - A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours. | 01-03-2013 |
20130005822 | AEROSOLIZED DAPSONE AS A THERAPY FOR INFLAMMATION OF THE AIRWAY AND ABNORMAL MUCOCILIARY TRANSPORT - Aerosolized dapsone (or alternatively, an aqueous formulation of dapsone) is used to treat airway inflammation, particularly chronic neutrophil-dominated inflammation. Diseases that may be prevented or treated by the methods include chronic obstructive pulmonary diseases (COPDs), asthma, cystic fibrosis, and others. | 01-03-2013 |
20130018104 | EMULSIVE COMPOSITION CONTAINING DAPSONE - The present invention relates to a topical, emulsive composition containing Dapsone or its derivative. The inventive composition incorporates emollients and Dapsone or its derivative in a stable emulsion. The stability is achieved through the use of a combination of certain surfactant mixtures and an enhancer providing solubility of the Dapsone. | 01-17-2013 |
20130079417 | Highly Selective 5-HT(2C) Receptor Agonists That Show Anti-Psychotic Effects with Antagonist Activity at the 5-HT(2B) Receptor - Highly selective 5-HT(2C) receptor agonists receptors are disclosed. The 5-HT(2C) receptor agonists are used in the treatments of disease and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders. | 03-28-2013 |
20130165526 | TOPICAL TREATMENT WITH DAPSONE IN G6PD-DEFICIENT PATIENTS - The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, and wherein the composition also contains dapsone in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The present invention also provides methods of treating dermatological conditions in G6PD-deficient patients with the composition, while avoiding adverse hematologic effects. | 06-27-2013 |
20130178536 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS - The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene. A method of treating or reducing the likelihood of Alzheimer's disease in a patient is an additional embodiment of the present invention. | 07-11-2013 |
20130225687 | COMPOUNDS AND METHODS FOR PKC THETA INHIBITION - The present invention provides a method of selectively inhibiting PKCθ in the presence of PKCδ, by administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I. The present invention also provides a method of inhibiting cytokine synthesis in a T cell, a method of inhibiting T cell proliferation, and a method of inhibiting the replication of and cytokine production by T lymphocytes, while not stimulating or inhibiting the replication of B lymphocytes. | 08-29-2013 |
20130245125 | HCl Polymorphs of 3-((2-(Dimethylamino)methyl(cyclohex-1-yl))phenol - A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)] phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states. | 09-19-2013 |
20130281539 | Highly Selective 5-HT(2C) Receptor Agonists That Show Anti-Psychotic Effects with Antagonist Activity at the 5-HT(2B) Receptor - Highly selective 5-HT(2C) receptor agonists receptors are disclosed. The 5-HT(2C) receptor agonists are used in the treatments of disease and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders. | 10-24-2013 |
20130296437 | Treatment of Depression - There is described a method of treatment of a patient suffering from depression, said method comprising the administration of a sub-analgesic amount of tramadol, or a salt thereof. | 11-07-2013 |
20140088199 | OPHTHALMIC TREATMENTS - Aqueous compositions suitable for topical administration to the human or animal eye contain at least one water-soluble polymeric ophthalmic lubricant, such as hyaluronate, carbomer gel or hypromellose, together with a water-soluble analgesic. The analgesic may be an opiod, particularly an opioid having an affinity for 5-HT receptors, such as tramadol. Typical tramadol levels would be in the range of 0.5% to 1.0% w/v. The aqueous compositions may for example be used as artificial tears, and as general ophthalmic lubricants for treating conditions such as dry eye or blepharitis. Further compositions combine ophthalmologically-active agents, such as pharmaceuticals, with opioids, such as tramadol in particular. These compositions may be used to treat the eye while reducing pain or discomfort that would normally be produced by administering these particular pharmaceuticals to the eye, and increasing the efficacy of the pharmaceuticals. Compositions are also disclosed, containing opioids with 5-HT receptor activity, which are of general use in alleviating pain in and around the eye. | 03-27-2014 |
20140107215 | CLENBUTEROL FOR USE IN TREATMENT OF AUTISM - Clenbuterol or its salt for use in the treatment of autism, in particular pediatric autism. Improved contact with surroundings, better concentration, improved ability to plan a specific task, improved understanding, calming, and reduced psychomotor anxiety were observed. | 04-17-2014 |
20140121282 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS - Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided. | 05-01-2014 |
20140155489 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM - The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ≧500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force. | 06-05-2014 |
20140171514 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY - The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride. | 06-19-2014 |
20140275276 | PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE - The present invention is directed to an aqueous formulation of S-ketamine hydrochloride, preferably for nasal administration, wherein the formulation does not contain an antimicrobial preservative. | 09-18-2014 |
20140275277 | PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE - The present invention is directed to an aqueous formulation of S-ketamine hydrochloride, preferably for nasal administration, wherein the formulation does not contain an antimicrobial preservative. | 09-18-2014 |
20140309310 | Pharmaceutical Composition for Preventing or Treating Disease with Bone Mass Loss Comprising Diaminodiphenylsulfone or Pharmaceutically Acceptable Salt Thereof - The present invention relates to a pharmaceutical composition for preventing or treating a disease with bone mass loss, which comprises diaminodiphenylsulfone (Dapsone; DDS) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition according to the present invention may be effectively used to prevent or treat a disease with bone mass loss such as osteopenia or osteoporosis by effectively restoring the reduction of bone density and bone mass. | 10-16-2014 |
20150031773 | Pharmaceutical Composition for Preventing or Treating Muscle Wasting-Related Disease Comprising Diaminodiphenylsulfone or Pharmaceutically Acceptable Salt Thereof - The present invention relates to a pharmaceutical composition for preventing or treating a muscle wasting-related disease comprising diaminodiphenylsulfone (Dapsone; DDS) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition according to the present invention may be effectively used to prevent or treat a muscle wasting-related disease by increasing muscle mass, preventing muscle loss and effectively restoring muscle function. | 01-29-2015 |
20150299102 | DERIVATIVES OF (-)-VENLAFAXINE AND METHODS OF PREPARING AND USING THE SAME - Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders. | 10-22-2015 |
20150335592 | MULTIPARTICLES SAFEGUARDED AGAINST ETHANOLIC DOSE-DUMPING - The invention relates to an oral pharmaceutical dosage form providing resistance against dose dumping in aqueous ethanol and comprising a pharmacologically active ingredient embedded in a matrix material,
| 11-26-2015 |
20160030572 | LIQUID FORMULATIONS - Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow. | 02-04-2016 |
20160030580 | TOPICAL DAPSONE AND DAPSONE/ADAPLENE COMPOSITIONS AND METHODS FOR USE THEREOF - Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder. | 02-04-2016 |
20160039742 | EXTRACTION OF TRAMADOL FROM NAUCLEA LATIFOLIA SMITH - A process for obtaining (±)-cis-2-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexanol includes the following steps: (a) extracting from roots of | 02-11-2016 |
20160051499 | COMPARATIVE EFFICACY AND TOLERABILITY OF DAPSONE 5% IN ADULT VERSUS ADOLESCENT FEMALES WITH ACNE VULGARIS - The present invention provides a method of treating facial acne vulgaris in an adult female (≧18 years of age) in need of such treatment, comprising topically administering dapsone 5% gel twice daily to the face of the adult female. | 02-25-2016 |
20160074341 | Methods for Overcoming Resistance to Tramadol - There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients. | 03-17-2016 |
20160106688 | Parenteral Administration of Tapentadol - An aqueous pharmaceutical composition adapted for parenteral administration of tapentadol or a physiologically acceptable salt thereof having a pH value of at least 5.4. | 04-21-2016 |
20160113890 | COMPOSITION FOR STIMULATING NEOVASCULARIZATION AT A SITE IN A SUBJECT COMPRISING DAPSONE AND USE THEREOF - A method of stimulating neovascularization at a site in a subject, or preventing or treating symptoms related to a decrease in vascularization in a subject, the method including administering dapsone or N-acetyl-dapsone, its pharmaceutically acceptable salt, a solvate, a polymorph, or a combination thereof to the subject; as well as related methods and compositions. | 04-28-2016 |
20160115121 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES - The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications. | 04-28-2016 |
20160145200 | NATURAL PRODUCT ANALOGS INCLUDING AN ANTI-INFLAMMATORY CYANOENONE PHARMACORE AND METHODS OF USE - This invention provides novel compounds comprising the following anti-inflammatory pharmacore: | 05-26-2016 |
20180021280 | Levodopa and Carbidopa Intestinal Gel and Methods of Use | 01-25-2018 |